Author:
Alí-Munive Abraham,Leidy Prada,Proaños Nadia Juliana,Pedrozo-Pupo John,Giraldo Angela,Cano Diana,Diaz-Bossa Claudia,Mosquera Ricardo,Paul Hector,Gonzalez-García Mauricio,Aguirre-Franco Carlos,López-Campos José Luis,Casas-Herrera Alejandro
Abstract
Abstract
Background
Alpha-1 antitrypsin deficiency (AATD) is an underrecognized genetic disorder associated mainly with pulmonary emphysema and Chronic Obstructive Pulmonary Disease (COPD). All individuals with COPD regardless of age or ethnicity should be tested for AATD, but in Colombia its prevalence in unknown.
Main objective
To determine the prevalence of the genetic mutations, present in AATD in adult patients with COPD in Colombia, using a genotyping test on cells from the oral mucosa.
Methods
This was a multicentre, observational, cross-sectional study which included adult patients attending seven COPD care centres in Colombia. Demographic data, medical history, including history of exposure to smoking and biomass smoke, most recent spirometry, pharmacological and non-pharmacological treatment received, serum AAT levels, and mutations detected by the genotyping test were recorded for all the recruited patients. For the comparison of variables between the groups with and without mutation, we used the X2 test for the qualitative variables and the Student’s t-test or Mann-Whitney U test according to their distribution.
Main findings
We collected a sample of 1,107 patients, the median age was 73.8 years (87.6–79.9). Mutations were documented in 144 patients (13.01%), the majority had the M/S mutation (78.50%), followed by M/Z (9.72%). One patient had a ZZ mutation and two patients had null alleles. In total, 23 patients had mutations associated with serum AAT deficiency (levels below 60 mg/dl).
Conclusions
Genetic mutations were documented in 13.01% of patients with COPD in Colombia and 2.07% were AATD-related, showing that there is a significant number of underdiagnosed patients.
Publisher
Springer Science and Business Media LLC
Subject
Pulmonary and Respiratory Medicine
Reference26 articles.
1. Cazzola M, Stolz D, Rogliani P, Matera MG: α(1)-Antitrypsin deficiency and chronic respiratory disorders. Eur Respir Rev 2020, 29(155):190073.
2. Asia Pacific CRG: Global Initiative for Chronic Obstructive Lung Disease strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: an Asia-Pacific perspective. Respirology 2005, 10(1):9–17.
3. de Serres FJ, Blanco I: Prevalence of α1-antitrypsin deficiency alleles PI*S and PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: a comprehensive review. Therapeutic Advances in Respiratory Disease 2012, 6(5):277–295.
4. De Serres FJ, Blanco I, Fernández-Bustillo E: Estimates of PI*S and PI*Z Alpha-1 antitrypsin deficiency alleles prevalence in the Caribbean and North, Central and South America. Monaldi Arch Chest Dis. 2009; 71(3): 96–105.
5. Martinez-González C, Blanco I, Diego I, Bueno P, Miravitlles M: Estimated prevalence and number of PiMZ genotypes of Alpha-1 antitrypsin in seventy-four Countries Worldwide. Int J Chron Obstruct Pulmon Dis 2021, 16:2617–2630.